

CURRICULUM VITAE

Wayne Batchelor, M.D., M.H.S., F.A.C.C., S.C.A.I.

Current Appointments Interventional Cardiologist, Southern Medical Group, P.A.
 Clinical Assistant Professor of Medicine
 Florida State University College of Medicine
 President, Tallahassee Research Institute
 Past-President, Southern Medical Group, P.A.
 Tallahassee, Florida, U.S.A.

Past Appointment Assistant Professor of Medicine 1999-2002
 University of Toronto
 Interventional Cardiologist
 Terrence Donnelly Heart Center
 St. Michael's Hospital
 Toronto, Ontario, Canada

Medical Licenses Medical License, State of Florida
 Medical License, State of Georgia

Active Certification

American Board of Internal Medicine

- Interventional Cardiology Certification
- Cardiovascular Medicine Certification

Royal College of Physicians and Surgeons of Canada

- Cardiovascular Medicine Certification (past)
- Internal Medicine Certification (past)

Education

1. Postgraduate

1998-99 Master's of Health Science in Clinical Research
 Duke University, Durham, NC

1996-99 Interventional Cardiology Fellowship
 Duke University Medical Center, Durham, NC

1996-99 Research Fellow, Division of Cardiology
 Duke University Clinical Research Institute

1995-96 Cardiology Research Fellow
 St. Michael's Hospital
 University of Toronto, Toronto, ON, Canada

1994-95 Adult Cardiology Fellowship
 University of Toronto, Toronto, ON, Canada

7. Mehran R, Nikolsky E, Kirtane AJ, Caixeta A, Wong SC, Teirstein PS, Downey WE, **Batchelor WB**, Casterella PJ, Kim YH, Fahy M, Dangas GD. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study. *JACC Cardiovasc Interv.* 2009 May;2(5):415-21.
8. Kereiakes DJ, Petersen JL, **Batchelor WB**, Fitzgerald PJ, Mehran R, Lansky A, Tsujino I, Schofer J, Dubois C, Verheye S, Cristea E, Garg J, Wijns W, Krucoff MW. Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial. *J Invasive Cardiol.* 2008 Jul;20(7):335-41.
9. Krumholz HM, Bradley EH, Nallamothu BK, Ting HH, **Batchelor WB**, Kline-Rogers E, Stern, AF, Byrd JR, Brush JE Jr. A Campaign to Improve the Timeliness of Primary Percutaneous Coronary Intervention: Door-to-Ballon: An Alliance for Quality. *J. Am. Coll. Cardiol. Interv.* 2008;1;97-104
10. Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, FitzgeraldPJ,Garg J, Turco MA, Simonton CA 3rd, Verheye S, Dubois CL, Gammon R, **Batchelor WB**, O'Shaughnessy CD, Hermiller JB Jr, Schofer J, Buchbinder M, Wijns W; COSTAR II Investigators Group. Multicenter Randomized Evaluation of a Novel Paclitaxel Eluting Stent With Bioresorbable Polymer for the Treatment of Single and Multivessel Coronary Disease: Primary Results of the Cobalt Chromium Stent With Antiproliferative for Restenosis II (COSTAR II) Study. *J. Am. Coll. Cardiol.* 2008; Apr 22;51(16):1543-52.
11. **Batchelor WB**, Peterson ED, Mark, DB, Knight DJ, Granger CB, MD, Armstrong PW, Califf RM. Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and Canada. *Am Heart J.* 2003 Feb;145(2):349-55.
12. **Batchelor WB**, Tolleson T, Larsen R et al. Direct Comparison of the pharmacodynamic profiles of Abciximab, Eptifibatide, and Tirofiban: Final Results of the COMPARE trial. *Circulation* 2002;106:1470-1476.
13. Berger PB, Mahaffey KW, Meier SJ, Buller CE, **Batchelor W**, Fry ET, Zidar JP; The ATLAST Investigators. Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. *Am Heart J* 2002;143(5):841-6.
14. Pasricha A, **Batchelor W**. When young hearts are broken: Profiles of premature myocardial infarction. *Am Heart J.* 2002 Jan;143(1):4-6.
15. **Batchelor WB**. From COURT to HOMBURG: in search of the optimal contrast agent. *Eur Heart J.* 2001 Nov;22(21):2026-8.
16. Bokhari F, **Batchelor W**. Percutaneous Coronary Intervention in the Management of Coronary Artery Disease. *Cardiology Grand Rounds*; Aug/Sep 2001(VI): 1-6.

18. **Batchelor WB** Kenneth W. Mahaffey, MD, FACC,* Peter B. Berger, MD, et al. A Randomised, Placebo-controlled Trial of Enoxaparin after High-risk Coronary Stenting: the ATLAST Trial. *Journal of the American Coll Cardiol* 2001 Nov 15;38(6):1608-13.
19. Jong P, Cohen EA, **Batchelor WB**, Lazzam C, Kreatsoulas C, Natarajan M, Strauss, BH. Bleeding Risks with Abciximab following Full-Dose Thrombolysis in Rescue or Urgent Angioplasty for Acute Myocardial Infarction. *Am Heart J.* 2001 Feb;141(2): 218-25.
20. **Batchelor WB**. Presentations in Focus (Invited Editorial). Reports and Expert Commentary. GP IIb/IIIa Inhibitors in Acute Coronary Syndromes: Preserving Myocardium. Medical Information Services. January 2000.
21. **Batchelor WB**, Anstrom KJ, Muhlbaier LJ, Grosswald R, Weintraub W, O'Neill WW, Peterson ED, for the National Cardiovascular Network Collaboration. Contemporary Outcome Trends in the Elderly Undergoing Percutaneous Coronary Interventions: Results in 7,472 Octogenarians. *J Am Coll Cardiol* 2000;36:723-30.
22. Morsi A and **Batchelor WB**. Platelet IIb/IIIa Antagonists in Acute Coronary Syndromes: An update on the major clinical trials. *Acute Coronary Syndromes.* 2000;2(4): 98-110.
23. **Batchelor WB**, Zidar JP. Fragmin and Other Low Molecular Weight Heparins in coronary artery intervention. *Current Interventional Cardiology Reports* 2000;2:41-48.
24. **Batchelor WB**, Granger CB, Kleiman NS, Phillips HR, Ellis S, Betriu A, Criger DA, Stebbins AL, Topol EJ, Califf RM for the GUSTO IIb Investigators. A Comparison of Ionic Versus Nonionic Low osmolar Contrast Medium Following Primary Percutaneous Coronary Angioplasty for Acute Myocardial Infarction: Results from GUSTO IIb. *Am J Cardiol.* 2000;85:692-696.
25. **Batchelor WB**, Peterson ED, Mark DB, Knight D, Granger C, Califf RM, Armstrong PW. A Comparison of U.S. and Canadian Post-MI Cardiac Catheterization Practices in Detecting Severe Coronary Artery Disease: Efficiency, Yield and Long-term Implications. *J Am Coll Cardiol.* 1999 Jul;34(1):12-9.
26. **Batchelor WB**, Zidar JD. Favorable vascular remodeling from self-expanding stents: magic or myth? *Am Heart J.* 1999 Aug;138:203-5.
27. Peterson ED, **Batchelor WB**. Percutaneous Interventions in the Very Elderly: Weighing the Risks and Benefits. *Am Heart J.* 1999 Apr;137:585-7.
28. **Batchelor WB**, Jollis JG, Friesinger GC. The Challenge of Health Care Delivery to the Elderly Patient with Cardiovascular Disease: Demographic, Epidemiologic, Fiscal and Health Policy Implications. *Cardiol Clin.* 1999 Feb;17(1):1-15
29. **Batchelor WB**, Robinson R, Strauss BH. The Extracellular Matrix in Balloon Arterial Injury: A Novel Target for Restenosis Prevention. *Progress in Cardiovascular Diseases* 1998;41(1): 35-49.

30. **Batchelor WB**, Butany J, Liu P, Silver MD. Cardiac Metastasis from Primary Cervical Squamous Cell Carcinoma: Three Case Reports and a review of the Literature. *Can J Cardiol* 1997;13(8):767-70.
31. **Batchelor WB**, Chisholm RJ, Natarajan MK et al. Dissections Following Excimer Laser-assisted Angioplasty in Saphenous Vein Bypass Grafts. *J Intervention Cardiol* 1996;9:265-269.
32. Strauss BH, Robinson R, **Batchelor WB**, Ravi G et al. In-vivo Collagen Turnover Following Experimental Balloon Angioplasty Injury and the Role of Matrix Metalloproteinases. *Circulation Research* 1996;79:541-550.
33. Natarajan MK, Strauss BH, **Batchelor WB** et al. Early and Late Quantitative Angiographic Results of Vein Graft Lesions Treated With Laser Angioplasty. *Circulation* 1995;92:348-356.
34. **Batchelor WB**, Heathcote JH, Wanless IR. Chaparral-Induced Hepatic Injury. *Am J Gastroenterol* 1995;90:831-33.

(Abstracts)

1. **Batchelor WB** and Mehran R “PLATINUM DIVERSITY: Outcomes from a large-scale, prospective registry of coronary artery stent implantation in women and minorities” TCT 2016.
2. Dahya V, **Batchelor WB** et al. CT-derived Skeletal Muscle Index: A Novel Predictor of Frailty and Hospital Length of Stay After Transcatheter Aortic Valve Replacement. Accepted for Presentation at AHA Scientific Sessions Nov 2016
3. Dahya, V, **Batchelor WB** et al. Body Composition Assessed by Computed Tomography Predicts Length of Stay After TAVR. Presented at SCAI meeting in May 2015.
4. Louis A. Cannon, MD; Dean J. Kereiakes, MD; **Wayne Batchelor, MD**; Albert Deibele, MD; James Hopkins, MD; Robert E. Foster, MD; Paul Underwood, MD; Keith D. Dawkins, MD. Long-Term Follow-up of the Platinum Chromium TAXUS Element (ION) Stent: PERSEUS Two-Year Results. TCT 2011.
5. **Batchelor WB**, Ellis SG, Ormiston J, Stone GW, Turco MA, Joshi A, Wang H, Underwood, PL. Long-Term Outcomes after Percutaneous Coronary Intervention with Paclitaxel-Eluting Coronary Stents in Black versus White Patients. AHA 2010.
6. Krucoff, W. Wijns, R. Mehran, A. Parhizgar, S. Verheye, C L. Dubois, **W B. Batchelor**, C D. O’shaughnessy, J L. Petersen, D J. Kerelakes: Multicenter Randomized Evaluation of a Novel Paclitaxel Eluting Stent with Bioresorbable Polymer for the Treatment of Single and Multivessel Coronary Disease: Primary Results of the COSTAR II Study. ESC Congress 2007.

7. R. Mehran, D. Kerelakes, A. Lansky, W. Wijns, P J. Fitzgerald, **W B. Batchelor**, C. Dubois, S. Verheye, M Webster M W. Krucoff : Overlapping Paclitaxel Eluting Stents: Early and Late Outcomes in the COSTAR II Study. ESC Congress 2007.
8. D J. Kereiakes, **W B. Batchelor**, P J. Fitzgerald, R. Mehran, W. Wijns, J. Schofer, J L. Petersen, C. Buboio, S. Verheye, M W. Krucoff : Clinical and Angiographic Outcomes in Diabetic Patients Following Single or Multivessel Stenting in the COSTAR II Randomized Trial:ESC Congress 2007.
9. W. Wijns, J L. Petersen, **W B. Batchelor** P B. Berger, C. Dubois, J A. Bittl, R S. Gammon, V. Hasselbiad, D J. Kerelakes, M. Krucoff: Outcomes for Stenting in Single and Multivessel Coronary Artery Disease Using Established and Novel Paclitaxel Eluting Stent Platforms: COSTAR II: ESC Congress 2007.
10. Kereiakes D, **Batchelor WB**, Berger P, Buchbinder M, Mehran R, Petersen J, Schofer J, Wijns W, Krucoff M, Verheye S: Thirty-day Outcomes Following Single and Multivessel Stenting in Diabetic Patients: Preliminary Results From the CoStar II Trial to be Presented at the TCT Meeting October 2007.
11. Berger P, **Batchelor WB**, Dubois C, Fitzgerald P, Gammon R, Hermiller J, Kereiakes D, Lansky A, Mehran R, O'Shaughnessy C, Turco M, Verheye S, Wijns W, Krucoff M: Evaluation of Paclitaxel-Eluting Stents in Single and Multi-vessel Coronary Artery Disease Using Established and Novel Stent Platforms: an Interim Analysis of the Randomized, Blinded COSTAR II Trial. TCT Meeting October 2007.
12. Mehran R, Kereiakes DJ, Berger P, Lansky A, Wijns W, Fitzgerald P, **Batchelor WB**, Dubois C, Turco M, Verheye S, Webster M, Litvak F, Krucoff MW. Overlapping Paclitaxel Eluting Stents: Early Outcomes in the COSTAR II Study Presented at the TCT Meeting October 2006.
13. Kassam S, **Batchelor WB**, Campbell A, Camack N, Latter, Fitchett DF, Stewart DJ. Direct Myocardial VEGF165 Injection as an Adjunct to Coronary Bypass Grafting: Comparison of Outcome Measures from a Prospective Trial. Presented at Canadian Cardiovascular Society Meeting, October 2001.
14. **Batchelor WB**, Radley D, Cohen M, Antman EM, Turpie AGG, Langer A, Goodman S. A comparison of the impact of practice patterns on the outcomes of patients with acute coronary syndromes in the USA and Canada: post-hoc analysis of ESSENCE and TIMI 11B. (American College of Cardiology Meeting, Orlando, March 2001).
15. **Batchelor WB**. Evaluating the Relative Efficacy and Side-effect Profiles of the IIb/IIIa Inhibitors: Pharmacodynamic Efficacy in the COMPARE study. The Transcatheter Cardiovascular Therapeutics Meeting 2000. October 19, 2000.
16. Labinaz M, Madan M, McGuire D, **Batchelor WB**, Saucedo J, Pacchiana C, Kitt M, O'shea CJ, Talley D, Liu H, Timmis S, Tchong JE. Effect of Eptifibatide, a

- Glycoprotein IIb/IIIa Antagonist, Among Diabetic Patients Following Coronary Stenting: Results from Esprit. (American Heart Association Meeting, November 2000).
17. Barolet, AW, Nili N, Robinson R, Natarajan, M, **Batchelor WB**, Singh I, O'Blenes S, Rabinovitch M, Strauss BH. Effect of Inhibition of Vessel Wall Elastase by Local Expression of Elafin on Neointima Formation in Response to Balloon Injury. (American Heart Association Meeting, November 2000).
 18. Berger P, Mahaffey KW, Buller CE, Deutsch E, Meier SJ, **Batchelor WB**, Zidar JP, for the ATLAST Investigators. Safety of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: Results from the ATLAST (Antiplatelet Therapy vs. Antiplatelet Therapy Alone in Patients at Increased Risk of Stent Thrombosis) trial. (American Heart Association Meeting, November 1999).
 19. Zidar JP, **Batchelor WB**, Berger P, Deutsch E, Fry E, Teirstein P, Ross A, Mahaffey KW, Meier S, Tipping D, and Berkowitz S, for the ATLAST Investigators. Does the low-molecular-weight heparin enoxaparin reduce stent thrombosis in high-risk stent patients? Results from ATLAST trial: Enoxaparin Plus Antiplatelet Therapy vs. Antiplatelet Therapy Alone in Patients at Increased Risk of Stent Thrombosis. (American Heart Association Meeting, November 1999).
 20. **Batchelor WB**. Comparative Pharmacodynamics of Glycoprotein IIb/IIIa Inhibitors. (Oral Presentation to be presented at symposium entitled: GP IIb/IIIa Inhibitors in Acute Coronary Syndromes: Preserving Myocardium, American Heart Association Meeting, November 1999).
 21. Zidar, JP, **Batchelor WB**, Berger PG, Deutsch E, Fry E, Ross A, Mahaffey AK, Meier, Berkowitz SD. Does the Low Does the Low-Molecular-Weight Heparin Enoxaparin Reduce Stent Thrombosis in High-Risk Patients? Results from the ATLAST Trial: Antiplatelet Therapy vs. Lovenox plus Antiplatelet Therapy for Patients with an Increased Risk of Stent Thrombosis (Presented at the Transcatheter Cardiovascular Therapeutics Meeting, Washington, D.C., U.S.A, September, 1999.)
 22. **Batchelor WB**, Peterson ED, Knight DJ, Armstrong PW, Granger CB. The use of a clinical predictive model for severe coronary artery disease improves the efficiency of cardiac catheterization in both the U.S. and Canada. (Presented at the American Heart Association 71st Scientific Session, November 1998.).
 23. **Batchelor WB**, Peterson ED, Anstrom K, Muhlbaier LH, Grosswald. Does stenting benefit the very elderly? An analysis of device-specific outcomes in 3,740 octogenarians. (Presented at the American College of Cardiology meeting March, 1998, Atlanta.).
 24. **Batchelor WB**, Peterson ED, Califf RM. Percutaneous Interventional Outcomes in Octogenarians: Insights from the National Cardiovascular Network Database. (presented at the American Heart Association Meeting, Orlando, November 1997)
 25. **Batchelor WB**, Granger C, Califf RM. Ionic, Low Osmolar Contrast is Associated with Better Outcome Following Direct PTCA: Results from Gusto IIb. (presented at the American Heart Association Meeting, Orlando, November 1997)

26. **Batchelor WB**, Binanay CA, Berkowitz SD et al. Antiplatelet Therapy vs. Lovenox plus Antiplatelet therapy for patients with an increased risk of Stent Thrombosis- The ATLAST Trial. (presented at the Symposium entitled “Discovery: the emerging role of LMWHs in ACS”, American Heart Association Meeting, Orlando, November 1997).
27. **Batchelor WB**, Robinson R, Chisholm R, Levy D, Keeley F, Strauss BH. Matrix metalloproteinase inhibition in balloon angioplasty: Effects on collagen turnover and intimal hyperplasia. (Presented at the American Society of Investigative Pathology, New Orleans, June 4, 1996).
28. **Batchelor WB**, Robinson R, Strauss BH. Insights into the role of the Extracellular Matrix in Restenosis: Decorin Expression in a Rabbit Model of Restenosis. (Presented at Ursula Bangs Cardiology Division Annual Research Day, University of Toronto, May 1995).
29. **Batchelor WB**, Freeman MR. Segmental Wall Motion Improves After PTCA in Stable Angina Pectoris and is Predicted by NTG Response and Thallium Reversibility. (Presented at Canadian Cardiovascular Society Meeting Oct. 1994).
30. Strauss BH, Natarajan MK, **Batchelor WB** et al. Quantitative Angiographic Analysis of Vein Graft Lesions treated with Excimer Laser Angioplasty: Immediate and Follow-up Results. (Presented at the American College of Cardiology meeting Mar. 1994).
31. **Batchelor WB**, Chisholm RJ, Natarajan MK, Adams LA, Strauss BH. Acute Dissection Following Laser Angioplasty in Saphenous Vein Grafts (Presented at Canadian Cardiovascular Society Meeting, Oct. 1993).

(Book Chapters)

1. **Batchelor WB**, Sketch MH, Stack RS. Perfusion Balloon Catheter. G. Roubin, W O’Neill, and R. Stack, eds. Interventional Cardiovascular Medicine, 2nd Edition. Churchill Livingstone 2001.
2. Strauss BH, **Batchelor WB**, Robinson R. Influence of Angioplasty on Matrix Signaling and Metabolism. in: A. Lafont and E. Topol, eds. Vascular Remodeling and Restenosis: Kluwer Academic Publishers 1996.

1. (Web Publications)

Batchelor WB et al. The importance of the PLATINUM DIVERSITY trial. **Cardiovascular News**. 24 Jun 2015 10:56: <http://www.cxvascular.com/cn-features/cardiovascular-news---features/the-importance-of-the-platinum-diversity-trial#sthash.ppEbIXUP.dpuf>

(Educational Tapes/CD-ROMs)

1. **Batchelor WB** and Grines CL. Does stenting benefit the very elderly? An analysis of device-specific outcomes in 3,740 octogenarians. American College of Cardiology Extended Learning Educational Tape Series 1998. April 1998;Vol. 30(4).
2. **Batchelor WB**, Binanay CA, Berkowitz SD et al. Antiplatelet Therapy vs. Lovenox plus Antiplatelet therapy for patients with an increased risk of Stent Thrombosis- The ATLAST Trial. Multimedia Highlights on CD-ROM from the American College of Cardiology Symposium: Discovery: the Emerging Role of Low-Molecular-Weight Heparins in Acute Coronary Syndromes, March 28, 1998.
3. **Batchelor WB** and Sketch MH. Percutaneous Interventional Outcomes in Octogenarians. American College of Cardiology Extended Learning Educational Tape Series February 1998;Vol. 30 (2).

(Television/Internet Educational Broadcasts)

1. Black and White: Racial Disparities in the Treatment of Patients with CAD. Smith CE, **Batchelor WB**. CME Web-based program for Heart.org. posted December 13, 2011: <http://www.theheart.org/article/1305943.do>.
2. Iodinated Contrast in Interventional Cardiology. **Batchelor WB** and Mehran R. CME Cybersession presented on The Heart.Org. June 6/2001.
3. General Electric Medical Systems TiP-TV Broadcast. "Contrast Imaging in Interventional Cardiology". Presenter and Panel Member. March 22, 2000

Honors and Awards

- | | |
|-----------|---|
| 2015 | Tallahassee Memorial Healthcare ICARE Award for Clinical Excellence. |
| 1999-2000 | Dean's Award for Excellence in Clinical Research
University of Toronto, Department of Medicine |
| 1996-99 | National Junior Research Fellowship Award
Heart and Stroke Foundation of Canada |
| 1996 | Dr. Jay Brown Fellows Award
Association of Black Cardiologists, Scientific Sessions
Orlando, FL, March 1996 |
| | Ursula Bangs Cardiology Resident Research Prize
University of Toronto:
<i>Decorin Inhibits Transforming Growth Factor Beta-1 Stimulation of Collagen Synthesis in Vascular Smooth Muscle Cells: Insights from adenoviral-mediated gene transfection</i> |
| 1995 | University of Toronto Department of Medicine
Resident Research Scholarship |

- Chisholm Memorial Resident Research Award
Faculty of Medicine, University of Toronto
- 1994 Ursula Bangs Cardiology Resident Research Prize
University of Toronto:
Segmental Wall Motion Improves After PTCA in Stable Angina Pectoris and is Predicted by NTG Response and Thallium Reversibility.
- 1992 Sopman Humanitarian Award for clinical/academic excellence and compassion
University of Toronto
- 1990 Dr. and Mrs. Sydney P. Schiff Medal in Surgery
Queen's University Medical School
- Nathan E. Berry Prize in Urology
Queen's University School
- 1989 Lange Medical Publications Book Award for Academic Excellence
- 1987 Heart and Stroke Foundation of Ontario
Student Research Scholarship
- Harry S. Jerome Scholarship for Academic Excellence
- 1986 James H. Rattray Memorial Scholarship, Life Sciences
Queen's University, ON, Canada
- 1984 Honors Matriculation Scholarship, Queen's University, ON, Canada
- 1984 Class Valedictorian, Frontenac Secondary School, Kingston, Canada
Ontario Scholar, Province of Ontario, Canada

Clinical Experience

1) Interventional Cardiology and Structural Heart Disease

Experienced and Currently Credentialed in:

Transcatheter Aortic Valve Replacement and Balloon Aortic Valvuloplasty
Percutaneous Mitraclip Mitral Valve Repair
Balloon Mitral Valvuloplasty
Left atrial appendage closure devices (Watchman and Lariat)
Radial Artery Coronary Interventions (over 4,500 cases performed)
Routine and High-risk/complex PCI
Carotid Artery Angiography and Stenting
Percutaneous Peripheral Vascular Intervention
Transeptal Catheterization

2) Coronary Intensive Care

Private Practice 2002-present

CCU Attending Physician in large teaching hospital 1999-Present

3) **Consultative Cardiology**

Private Practice 2002-present

Consulting Cardiologist in large teaching hospital 1999-Present

Professional Associations/Memberships

Fellow of the American College of Cardiology

Fellow of the Society of Cardiac Angiography and Intervention

American Heart Association- Member

Fellow, Royal College of Physicians and Surgeons of Canada (past)

Delegate, Florida Medical Association 2002 (past)

American Heart Association- Clinical Cardiology Council Member 1999-2002

Association of Black Cardiologists (ABC) - Board Member and lifetime member

Capital Medical Society- Member

Medical Journal Peer Review

Past Ad hoc reviewer for following journals:

- Circulation

- American Journal of Cardiology

- American Heart Journal

- Journal of the American College of Cardiology

Committees/Invited Faculty

2015- Present Vice President and Board Member

Duke University Cooperative Cardiovascular Society

2013- Present

Chair, Interventional Cardiology Council.

Tallahassee Memorial Hospital

2011- Present

Co-Director, SMG/TMH Structural Heart Program

2010- 2015

Chair, Cardiac Case Review Committee

Tallahassee Memorial Hospital

2015

Tallahassee Mayor's Summit on Healthcare

2013

Tallahassee Mayor's Summit on Healthcare Disparities

2009-2010

Chair, Medical Executive Committee

Tallahassee Memorial Hospital

2006-2009

American College of Cardiology Door to Balloon Time (D2B)

National Taskforce Member. (Chair of Toolkit Subgroup)

2006-2007	American College of Cardiology, Florida Chapter, Vice-Chair, Committee on Cardiac Catheterization.
2006	Executive Steering Committee Member for the VICTORY-LTCAD study.
2006-2008	Chair, Carotid Stent Review Committee Tallahassee Memorial Hospital
2006-Present	Medical Advisory Board, Boston Scientific
2005-Present	Member of Medical Staff Executive Tallahassee Memorial Hospital
2005-Present	Chair, Cardiac Case Review Committee Tallahassee Memorial Hospital
2007-Present	President, Tallahassee Research Institute
2004-Present	Member, Tallahassee Memorial Hospital Institutional Review Board.
2004	Invited Faculty. Intervention 2004. Moderator and Panel Member.
2002	Invited International Faculty for Transcatheter Cardiac Therapeutics (TCT) Meeting, October 2002. Moderator and Presenter.
2001	Invited International Faculty for Transcatheter Cardiac Therapeutics (TCT) Meeting, October 2001. Moderator and Presenter.
2000	Invited International Faculty for Transcatheter Cardiac Therapeutics (TCT) Meeting, October 2000. Moderator and Presenter.
1999	Invited International Faculty Member for Transcatheter Cardiac Therapeutics (TCT) Meeting, September 1999. Presenter.
1999	Consensus Conference on the Management of ACS. Sponsored by Canadian Heart Research Centre. Panel Participant.
1997-98	American Medical Association/Association of American Medical Colleges Clinical Research Focus Group - U.S. national gathering of thought leaders to discuss the future of clinical research.
1994-96	Camp Jumoke Committee for Children with Sickle Cell Disease. -Vice-Chair and Medical Director, Toronto, ON Canada

- 1994-95 Association for the Advancement of Blacks in the Health Sciences - Founding Board Member, and Educational Officer. Toronto, ON, Canada
- 1993-94 Committee of Postgraduate Training in Cardiology Resident Representative, University of Toronto, ON Canada
- 1992-93 Committee of Postgraduate Training in Internal Medicine Resident Representative, University of Toronto
- 1991-92 Resident's Representative for Ambulatory Internal Medicine Clinic Planning Committee

Teaching Experience

- 2002-Present Medical Student, Family Practice and Internal Medical Resident Clinical Teaching
Florida State University College of Medicine
- 1999-2001 University of Toronto Medical Student Teaching
Years II, III, IV Students
- 1997-98 Duke University Ambulatory Medicine Clerkship
Clinical Teaching for Year 2 and 3 Medical Students
- 1992-93 University of Toronto Clinical Skills Course
Year 2 Medical Student Teaching, 8-week course
- 1993-94 Electrocardiography Course For Fourth Year Medical Students
Developed and taught three 8-week courses (1hr./wk.)

Invited Lectures (Too extensive, not updated Since 2009)

1. "Novel Strategies for Treating LM with PCI. South Atlantic Cardiovascular Conference. August 2009.
2. "Five Cases of Left Main Percutaneous Coronary Intervention: Do the risks outweigh the benefits. Invited Lecturer and Faculty. South Atlantic Cardiovascular Conference. August 2009.
3. "A Clinician and Clinical Investigator in Private Practice". Invited Lecturer and Faculty. Fellows Training Forum. American College of Cardiology 55th Scientific Session, March 2006.
4. Achieving Rapid Reperfusion for Acute Myocardial Infarction: Current State of the Art. Invited Keynote Speaker. Big Bend Medical Society Meeting, December 2006.
5. "Pursuing Perfection with the Institute of Healthcare Improvement": The Tallahassee Memorial Hospital Experience 2001-2004. Invited Lecturer. The American College of Cardiology Meeting March 2005.
6. "Biotech and Health Disparities: New Options and Opportunities for Treating Obesity, Diabetes, Heart Disease, HIV/AIDS and Sickle Cell Anemia." Invited Lecture. The Institute for African American Health. April 2, 2004.
7. "New Paradigms for Treating Acute Coronary Disease: Recent Advances in Catheter-Based and Pharmacologic Interventions." Invited Keynote Speaker. Capital Medical Society Meeting January 2004.

8. "Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy: Past, Present and Future" Invited Lecture. Tallahassee Heart & Vascular Annual Meeting 2003.
9. "Prevention and Intervention of Coronary Artery Disease in the Elderly Patient". Invited Lecture. Transcatheter Cardiovascular Therapeutics Meeting 2002. Washington, D.C. Sept 2002.
10. "New Insights into the Relative Potency and per Patient Variability of GP IIb/IIIa Inhibitors: Results of the COMPARE Study. Invited Lecture. Transcatheter Cardiovascular Therapeutics Meeting 2002. Washington, D.C. Sept 2002.
11. "Acute Coronary Syndromes: Cath Lab Issues with Antithrombotic Therapy". Invited Lecturer. CME Satellite Symposium of the International Heart Failure Summit. July 3, 2001, Toronto.
12. "Interventional Cardiology 2001: Toward Optimal Efficacy and Safety". Invited Lecturer. York-Finch Medical Grand Rounds. June 14, 2001.
13. "Update in Clinical Trials". Co-Chair and Presenter. St. Michael's Hospital Annual Cardiology Update. March 31, 2001.
14. "Intervention in Acute Coronary Syndromes: Too much, or just enough?" St. Michael's Hospital Annual Cardiology Update. Invited Lecture. CHE event March 31, 2001.
15. "Secondary prevention of Vascular Ischemic Attacks". Invited Keynote Speaker for Bristol Myers Squibb's 4th Annual Cardiovascular Day. March 5, 2001, Toronto, Ontario, Canada.
16. "Current Controversies in Contrast Imaging in Interventional Cardiology" Invited Lecture. Premier Cardiovascular Subcommittee, Orlando Florida, February 5, 2001.
17. "Update on oral antithrombotic therapy to prevent vascular disease progression". Invited Lecture/CHE event sponsored by Bristol-Myers Squibb. November 18, 2000, Toronto, Ontario, Canada.
18. "COURT Dismissed: Ionic Contrast Media remains the gold standard for use in PCI". Transcatheter Cardiovascular Therapy Meeting, Washington, D.C., October 21, 2000. Invited Debate participant and Lecturer.
19. "Pharmacodynamics of GP IIb/IIIa Inhibitors". Invited Lecturer and Moderator, Transcatheter Cardiovascular Therapy Meeting, Washington, D.C., October 19, 2000.
20. "Therapeutic Angiogenesis: Where are we going? A proposal for a clinical trial". University of Toronto City-wide Cardiology Rounds. Invited Lecture. October 12, 2000.
21. "The Role of Coronary Intervention in Acute Coronary Syndromes". St. Michael's Hospital Critical Care Medicine Lecture Series. Invited Guest Lecturer. October 3, 2000.
22. "Oral Antiplatelet Therapy for Secondary Prevention." Peel Memorial Hospital Grand Rounds. Invited Lecturer, Medical Grand Rounds, September 15, 2000.

23. "Low Molecular Weight Heparin in Percutaneous Coronary Intervention: How "NICE" does the Future Appear". Invited Lecture. Aventis CME program. September 30, 2000.
25. "Contrast and Thrombosis in Interventional Cardiology". Mallinckrodt National Sales Meeting. Invited Keynote Speaker, September 22, 2000, Milwaukee, WI.
26. "A Practical Approach to the Treatment of Hypertension and Concomitant Diseases". Invited Lecturer for Fournier CME event. June 3, 2000.
27. "Pharmacodynamic Considerations when selecting a GP IIb/IIIa Inhibitor in PCI." Invited Lecture. Cor Therapeutics-sponsored CME Symposium: "New Insights into the Management of Patients with Non-ST segment Acute Coronary Syndromes in the CCU Setting." May 20, 2000, Las Vegas, Nevada.
28. "Contrast Media- An update for the Interventional Cardiologist". Planning member for Speaker's Bureau, and invited lecturer. Atlanta, GA, April 7-9, 2000.
29. "Contemporary risk stratification and anti-thrombotic strategies for unstable coronary artery disease:." Scarborough General Hospital Grand Rounds, April 11, 2000.
30. "Walking the Tightrope: Coronary Intervention in the high risk patient". Lecturer at St. Michael's Hospital Terrence Donnelly Heart Center Cardiology day Symposium: "Cardiology for the Practitioner: Critical pathways for the new millennium. Toronto, Ontario Canada. March 2000.
31. "Contrast Imaging in Interventional Cardiology. Tip T.V. Broadcast (The Health Channel Online). Invited speaker for a television-based CME program. March 29, 2000.
32. "COMPARE Trial Results: Comparative Pharmacodynamics of GP IIb/IIIa Inhibitors." Invited Lecture presented at Satellite Symposium entitled: New Concepts on the use of GP IIb/IIIa Inhibitors, American College of Cardiology Meeting, Anaheim, California, March 11, 2000.
33. "Low-Osmolar Contrast is Associated with Improved Outcomes in Direct PTCA for Acute Myocardial Infarction: Insights for GUSTO-IIb". Invited Lecture at the Tremblant, Quebec Interventional Cardiology Review Course, February 4th, 2000.
34. "Intravascular Contrast Media in Interventional Cardiology: a clinician's perspective". Invited Lecturer for National Sales Training Meeting for Mallinckrodt, January 24, 2000.
35. "Glycoprotein IIb/IIIa Inhibition in Acute Coronary Artery Disease": A Review of the Evidence Base. Invited Lecture, Division of Cardiology, Sudbury, Ontario. December 6, 1999.
36. "Is Universal Stenting indicated in the Era of GP IIb/IIIa Inhibition?" Invited Lecture, University of Toronto Division of Cardiology, City-Wide University Rounds December 2, 1999.

37. "Indications for Cardiac Catheterization in Acute Coronary Syndromes: A Contemporary Perspective." Scarborough Centenary Health Centre, Cardiology Grand Rounds, November 1999.
38. "Current Anti-thrombotic Therapies for Coronary Artery Disease": Focus on GP-IIb/IIIa Inhibition. Invited Speaker for Evening CME Symposium Sponsored by Merck, Canada. November 1999.
39. "In Search of Methuselah: Evaluating the Risk-benefit Relationship of Percutaneous Coronary Interventions in the Elderly". St. Michael's Hospital Grand Rounds, September 15, 1999.

Research Interests

1. New device technology evaluation in structural heart, carotid, peripheral vascular, and coronary interventions
2. Cardiovascular health care disparities in minorities
3. Defining frailty in elderly patients undergoing complex structural heart interventions.
4. National practices to optimize clinical outcomes in acute myocardial Infarction and improve door to balloon times.
5. Antithrombotic therapies in percutaneous coronary interventions and acute coronary syndromes
6. Reduction in healthcare disparities in minorities and women.
7. Regional and international variability in percutaneous coronary interventional practices
8. Health outcomes of percutaneous coronary interventions in the elderly
9. Contrast media- antithrombotic properties and nephrotoxicity
10. Clinical trials and outcomes research

Clinical Research

1. National co-Principal Investigator for the PLATINUM Study. A study evaluating outcomes in 1,501 women and minorities following PCI. Responsible for study concept and design, protocol development, site recruitment, study management and leadership, and manuscript preparation
2. Site Principal Investigator for following recent clinical trials (list is not exhaustive)
 - U.S. TENDYNE Study
 - U.S. SALUS Study
 - HARMONEE Study
 - ABSORB II and III studies
 - ACCELERATE Study
 - EVOLVE II Study
 - COAPT Study
 - RIVER-PCI study
 - TRYTON Study
 - CABANA Study
 - INNOVATE-PCI study
 - SAPPHIRE Study
 - PERSEUS Study
 - PLATINUM
 - PRESTO Study
 - COURAGE Study
 - CREDO Study
 - MEDSTENT Study
 - Octogenarian QOL PCI study (Study Chairman)
 - TESTED ASIANS Study (Study Chairman)
 - ICON Study
 - COMPARE Study (Study Chairman)
 - NORTHERN Study (Study Chairman)
 - DELTA MI
 - CHAMPION- PCI Study
 - COSTAR
 - CAPTURE 2

<u>Research Funds/Grants</u>	<u>Purpose</u>	<u>Amount</u>	<u>Period</u>
PRAGMATIC STUDY	A randomized trial evaluating a sheathless approach to PCI vs a standard sheath/guide catheter system.	\$75, 000	2016-2017
SMARTIST-3 Study (Co-investigator)	A Multi-Centre, Randomized, Double-blind, Placebo-controlled Trial of Myocardial Angiogenesis using VEGF ₁₆₅ Endomyocardial	\$500,000	2001-2003

Gene delivery in Patients
with Severe Angina Pectoris

TESTED-ASIANS Study (Primary Investigator)	A Clinical Study assessing Ethnic Differences in Endothelial Function	\$100,000	2000-01
COMPARE trial (Primary Investigator)	Investigator-initiated Clinical Trial of Platelet IIb/IIIa inhibition During PTCA	\$270,000	1999-2001
Dean's Award (Primary Investigator)	University of Toronto Clinical Research Support For a Long-term Study of Quality of Life in Elderly Patients Undergoing PTCA	\$10,000	1999-2001
Heart and Stroke Fdn. of Canada	National Research Award	\$130,000	1996-99
Chisholm Memorial Research Award	Research Fellowship	\$10,000.00	1995-96
University of Toronto Dept. of Medicine Research Award	Research Fellowship	\$10,000.00	1995-96